

AMC BROADGATE QUANT 1

As of 31 July 2025

OBJECTIVE

To efficiently harvest rewarded systematic risk premia in the market, while eliminating unrewarded risk exposures, allowing investors to earn higher returns per unit of risk.

INVESTMENT STRATEGY & PROCESS

The portfolio is based on Broadgate's Quantitative Multi-Factor Model. It focuses on the proper management of "factor exposures" as the main source of performance and looks through asset class decompositions to focus on underlying factor decomposition. It aims to invest in an equal-weighted portfolio of 40 equity names in developed markets, selected based on Broadgate's proprietary Multi-Factor model. The strategy aims to outperform the benchmark – MSCI World index – by following an allocation determined by the intensity of factors (Momentum, Value, Low Volatility, Quality and Growth). Factors are built in-house, using proprietary descriptors with high return explanatory powers and a unique weighting scheme that allocates dynamically among the factors. The portfolio is rebalanced monthly, and the methodology is continuously reviewed by Broadgate's quant research team.

PRODUCT CHARACTERISTICS

Product	AMC Broadgate Quant 1
ISIN	➤ FRELU0003488
Issuer/Guarantor	Exane Solutions Luxembourg (SA) / BNP Paribas Moody's: Aa3; S&P: A+; Fitch AA-
Underlying	> Broadgate Quant 1 Dynamic Portfolio
Actively Managed	Yes, by Broadgate Advisers
Maturity	▶ Open-End
Denomination	▶ 1'000 USD
Currency	▶ USD
Total Management Fees	 1.25% p.a. (i.e 0.25% to Exane Solutions and 1.00% to Broadgate Advisers) + 10% Performance fees based on high watermark over an initial hurdle of 107%
Liquidity	▶ Daily
Pricing Publication	➤ Telekurs, Bloomberg
NAV	▶ USD 1202.09 (as of July 31 st , 2025)

AMC Manager Comment

The strategy was up by 1.6% in July while MSCI World was up by 1.2%.

Attribution: Last month most sectors were in the green, with *Information Technology 5.2*% and *Utilities 4.9*% being the top performers. *Healthcare -3.3*% and *Consumer Staples -2.4*% were the worst performers. Broadgate Quant mandate outperformed the market by 0.4%, due to positive selection (0.5%), partially offset by negative currency (-0.1%) effect.

Positive selection mainly from Healthcare: Orion up 7.4%, Johnson & Johnson 7.9% and Resmed 5.4%; Communication Services: underweight Netflix -13.4%. Negative currency effect due to overweight GBP and SEK.

Factor Sensitivity (Beta): The current top style exposures are, by order, Quality, Momentum and Growth.

HISTORICAL PERFORMANCE Cumulative Performance (basis USD)



Performance snapshot of the share class - Actual 15.09.21 - 31.07.25

		Quant 1*	World
Performance (%)	1 Month	1.63	1.23
	3 Months	12.26	11.50
	YTD	7.86	9.93
	Since Inception	20.21	30.32
Risk (ex-post)	Annualized Volatility (%)	18.07	15.43
	Correlation	0.91	
	Tracking Error (%)	7.54	
	Beta	1.07	
Risk/Return	Sharpe Ratio	0.28	0.45
	Information Ratio	-0.21	

AMC Broadgate Quant 1

Broadgate MSCI



AMC BROADGATE QUANT 1

As of 31 July 2025









Portfolio Contribution

Best Performers


Components	MTD Performance
ARISTA NETWORKS INC	20.44%
ALLEGION PLC	15.13%
NVIDIA CORP	12.58%
APPLOVIN CORP-CLASS A	11.60%
AVANZA BANK HOLDING AB	10.21%
ALPHABET INC-CL A	8.89%
META PLATFORMS INC-CLASS A	8.88%
JOHNSON & JOHNSON	7.85%
ORION OYJ-CLASS B	7.40%
MICROSOFT CORP	7.26%

Worst Performers


Components	MTD Performance
PALO ALTO NETWORKS INC	-15.17%
MICRON TECHNOLOGY INC	-9.13%
ADOBE INC	-7.54%
MONSTER BEVERAGE CORP	-6.21%
ZOETIS INC	-6.20%
PARAGON BANKING GROUP PLC	-5.89%
JACK HENRY & ASSOCIATES INC	-5.75%
SALESFORCE INC	-5.27%
FORTNOX AB	-4.86%
ELECTRONIC ARTS INC	-4.51%

Portfolio Allocations

Breakdown by Geography



Breakdown by Sector



For more Information :

Broadgate Advisers

Tel: +41 (0)22 316 0060 Email: Quant1@broadgate.ch Internet: https://broadgateadvisers.com/

BNP Paribas Suisse SA

Email: joris.maillet@bnpparibas.com

This document/communication may contain "Research" as defined under MFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MFID II unbundling rules and have signed up to a BNP Paribas Global Markets Research package, or (ii) for firms that are out of scope of the MFID II unbundling rules and therefore are not required to pay for Research under MFID II. Please note that it is your firm's responsibility to ensure that you do not view or use any Research in this document. If your firm has not signed up to a BNP Paribas Global Markets Research package, unless your firm is out of scope of the MFID II unbundling rules. This document may also be regarded as a minor non-monetary benefit (MNMB) and it is your firm's responsibility to consider its own regulatory obligations in relation to inducements and accepting MNMBs. This document is considering the communication and has been prepared by a Sales and Marketing function within BNP Paribas and (in the substitution of the Sales and Marketing function within BNP Paribas and (in the substitution of the Sales and Marketing function within BNP Paribas within the comment of the substitution of the sub